BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement

2025-01-01 to 2025-12-31

Swipe to see the full flow
BIOGEN INC. (BIIB) FY2025 Annual P&L / Income StatementIncome statement for 2025-01-01 through 2025-12-31. View: Product and service (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETProduct revenue, netRevenue from anti-CD20 therapeutic programsContract manufacturing revenueAlzheimer's collaboration revenueRoyalty and other revenueRevenuesGross profit (calculated)Cost of sales, excluding amortization and impairment of acquired intangible assetsOperating profit (calculated)Operating expenses (calculated)Selling, general and administrativeResearch and developmentAmortization and impairment of acquired intangible assetsAcquired in-process research and development, upfront and milestone expenseCollaboration profit sharing/(loss reimbursement)Impairment of ROU assetRestructuring charges(Gain) loss on fair value remeasurement of contingent considerationOther (income) expense, netIncome before income tax (benefit) expenseNet incomeIncome tax (benefit) expenseGross profit (calculated)Gross profit(calculated)$7.49 BOperating profit (calculated)Operating profit(calculated)$1.56 BIncome before income tax (benefit) expenseIncome before incometax (benefit) expense$1.56 BRevenuesRevenues$9.89 BNet incomeNet income$1.29 BOperating expenses (calculated)Operating expenses(calculated)$5.93 BProduct revenue, netProduct revenue, net$7.12 BIncome tax (benefit) expenseIncome tax(benefit) expense$263.60 MSelling, general and administrativeSelling, general and administrative$2.43 BResearch and developmentResearch and development$1.78 BRevenue from anti-CD20 therapeutic programsRevenue from anti-CD20therapeutic programs$1.86 BCost of sales, excluding amortization and impairment of acquired intangible assetsCost of sales$2.40 BAmortization and impairment of acquired intangible assetsAmortization and impairmentof acquired intangible assets$515.00 MContract manufacturing revenueContract manufacturing revenue$679.40 MAlzheimer's collaboration revenueAlzheimer's collaboration revenue$177.70 MAcquired in-process research and development, upfront and milestone expenseAcquired in-process researchand development, upfrontand milestone expense$471.80 MRoyalty and other revenueRoyalty and other revenue$53.50 MCollaboration profit sharing/(loss reimbursement)Collaboration profitsharing/(loss reimbursement)$290.20 MImpairment of ROU assetImpairment of ROU asset$52.90 MRestructuring chargesRestructuring charges$48.60 M(Gain) loss on fair value remeasurement of contingent consideration(Gain) loss on fairvalue remeasurement ofcontingent consideration$33.60 MOther (income) expense, netOther (income) expense, net$305.60 M
Chart details

BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Product and service (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues
9,890,600,000 US dollars
Cost of sales, excluding amortization and impairment of acquired intangible assets
2,404,200,000 US dollars
Gross profit (calculated)
7,486,400,000 US dollars
Operating expenses (calculated)
5,929,900,000 US dollars
Operating profit (calculated)
1,556,500,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Income before income tax (benefit) expense
1,556,500,000 US dollars
Income tax (benefit) expense
263,600,000 US dollars
Net income
1,292,900,000 US dollars
Product revenue, net
7,119,400,000 US dollars
Royalty and other revenue
53,500,000 US dollars
Alzheimer's collaboration revenue
177,700,000 US dollars
Contract manufacturing revenue
679,400,000 US dollars
Revenue from anti-CD20 therapeutic programs
1,860,600,000 US dollars
Research and development
1,778,600,000 US dollars
Selling, general and administrative
2,433,600,000 US dollars
Amortization and impairment of acquired intangible assets
515,000,000 US dollars
Gain on sale of priority review voucher, net
0 US dollars
Collaboration profit sharing/(loss reimbursement)
290,200,000 US dollars
Other (income) expense, net
305,600,000 US dollars
(Gain) loss on fair value remeasurement of contingent consideration
33,600,000 US dollars
Restructuring charges
48,600,000 US dollars
Acquired in-process research and development, upfront and milestone expense
471,800,000 US dollars
Impairment of ROU asset
52,900,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
BIOGEN INC. (BIIB) FY2025 Annual Revenue by Product and Service (5 categories) Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

75.7%

Gross profit / revenue

Operating margin

15.7%

Operating profit / revenue

Cash conversion

170.5%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!